natgillin/translations-raw huggingface dataset:
A process in accordance with claim 1, wherein compound (ii) is prepared in about 97% enantiomeric excess. 
Spoj u skladu s patentnim zahtjevom 1 odabran iz skupine koja se sastoji od:
imaging said patient. In certain preferred embodiments, the arginase overexpression is associated with asthma, cancer, bacterial infections, or combinations thereof. 
Spoj ili kemijski sastav za upotrebu temeljem zahtjeva 9, naznačen time da je navedena prekomjerna ekspresija arginaza povezana s astmom, rakom, bakterijskom infekcijom, ili njihovom kombinacijom.
and R3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R7; 
Ri R* zajedno sa atomom dušika na koji su spojeni tvore zasićeni mono, biciklički ili premošteni sustav prstena koji opcijski sadrži 1 ili 2 dodatna heteroatoma prstena odabranih od dušika, kisika i sumpora i koji su opcijski spojeni na zasićeni, djelomično zasićeni ili nezasićeni monociklički prsten pri čemu je sustav rezultirajućeg prstena opcionalno supstituiran sa 1, 2, ili 3 supstituenta nezavisno odabranih od R',
As shown in above tables, the compound of formula III is surprisingly a high affinity PPARY partial agonist With PPARa activity. 
Kao što je prikazano u tablicama, gore, spoj formule III je iznenađujuće visokoafinitetni parcijalni agonist PPARy s aktivnošću na PPARa.
Preferably the processing agent is added in amounts from 0.01 wt. % to about 5 wt. %, more preferably from about 0.05wt. % to about 4 wt. %, still more preferably from about 0.4 wt % to about 3wt. %, based on the dry weight of the slurry. In a particular embodiment, the processing agent is aluminum sulfate. 
Postupak prema jednom od zahtjeva 1 do 11, naznačen time da se sredstvo za obradu dodaje u količinama od 0.01 tež.% do oko 5 tež.%, poželjnije od oko 0.05 tež.% do oko 4 tež.%, još poželjnije od oko 0.4 tež.% do oko 3 tež.%, bazirano na suhoj težini suspenzije.
for a compound of Formula I wherein A is OR10 coupling a corresponding compound having the Formula V with a compound having the formula HO-R10 in the presence of a coupling agent and triphenylphosphine in a suitable solvent; or 
R' sa spojem formule HO-R'" u prisutnosti sredstva za spajanje i trifenilfosfina u prikladnom otapalu; ili (d) za spoj Formule I gdje B je (CH>)NR'R", reakciju odgovarajućeg spoja Formule VI s hidrazinom; ili
The starting material of formula III are either commercially available or can be prepared by methods analogues to those described in the literature (e.g. Berridge, M. S. et al. J. Med. 
Pokazna supstanca formule III je ili komercijalno raspoloživa ili se može pripraviti na načine poput onih opisanih u literaturi (npr. Berridge. M.S. 1 sur. J Med.
Bound and free [3H]Mesulergine was separated by vacuum filtration on GF/B filters (pre-soaked in 0.1% PEI for ½ hour) and counted in a scintillation counter. 
Vezani 1 slobodni [*H] mesulergine je odijeljen vakuumskom filtracijom kroz GF/B filtere (prije toga "% sata namočene u 0,1% PEI) i prebrajan pomoću bljeakajućeg brojača.
at least two opposing and spaced apart jacks adapted to function in identical fashion to assist in raising and lowering of the at least two elongate holding members relative to the fixed support structure, each jack comprising: 
najmanje dvije nasuprotne i razmaknute dizalice (50,150) prilagođene da funkcioniraju na identičan način za pomoć u podizanju i spuštanju barem dva izdužena držača (14,114) u odnosu na fiksnu potpornu strukturu (16,116).
Aclidinium for use according to claim 1 or 2, wherein the respiratory patient suffers from asthma or chronic obstructive pulmonary disease (COPD). 
Aklidinij za primjenu prema zahtjevu 1 ili 2, naznačen time, što respiratorni bolesnik pati od astme ili kronične opstruktivne plućne bolesti (KOPB).
A pharmaceutical composition for oral administration comprising a therapeutically effective amount of 5-azacytidine, which releases the 5-azacytidine substantially in the stomach and achieves a time to maximum plasma concentration of less than about 90 minutes following oral administration. 
Farmaceutski pripravak za upotrebu u postupku liječenja subjekta koji ima rak koji obuhvaća oralno davanje farmaceutskog pripravka subjektu koji se sastoji iz terapeutski učinkovite količine 5-azacitidina, pri čemu pripravak je pripravak s trenutnim oslobađanjem i pri čemu je rak akutna mijelogena leukemija.
represents hydrogen, C1-4 alkyl group, phenyl or optionally substituted phenyl; 
R" predstavlja vođik, C,., alkil skupinu, fenil ili opcijski supstituirani fenil;
The pharmaceutical composition of claim 1, wherein the second portion is selected from the group consisting of an Fc region, albumin, a PAS sequence, transferrin, CTP (28 amino acid C-terminal peptide (CTP) of hCG with its 4 O-glycans), polyethylene glycol (PEG), hydroxyethyl starch (HES), albumin binding polypeptide, albumin-binding small molecules, and two or more combinations thereof. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 5, naznačen time što drugi dio obuhvaća Fc regiju, albumin, PAS sekvencu, transferin, CTP (C-terminalni peptid od 28 aminokiselina (CTP) od hCG sa 40- glikanima), polietilen glikol (PEG), hidroksietil škrob (HES), albumin vezujući polipeptid, male molekule koje vežu albumin, ili dvije ili više njihovih kombinacija.
administering to a subject in need thereof an amount of a compound according to Formula I: 
Sol maleinske kiseline spoja prema formuli I:
The energy savings device of claim 1, wherein said at least one phase input connection is bi-phase input system. 
Sustav za uštedu energije iz zahtjeva 1, gdje sustav obuhvaća jedan način za komuniciranje s najmanje jednim računalnim uređajem.
In particular, said fixing means, in the medical field are selected from the group comprised of: 
Uređaj prema zahtjevu 1, pri čemu su sredstva (80,100) za pričvršćivanje, u oblasti medicine izabrana iz grupe koja se sastoji iz:
a puncturing means configured to perform puncturing on the generated LDPC parity bits. The transmitter of claim 1 or 2, wherein the time interleaver is configured not to perform a time-interleaving process on the bit-interleaved L1 signaling data for the case that the L1 TI mode information indicates no time interleaving mode. 
Predajnik iz bilo kojeg zahtjeva od 1 do 3, naznačen time da je među-pohrana konfigurirana da ne izvodi postupak vremenske među-pohrane na vrijednostima skupa iz mape koje odgovaraju odašiljanim podacima sloja 1, u slučaju da L1 TI način informiranja ne pokazuje način vremenske među-pohrane.
the covering of this core element with a strip of impregnable flexible material which continues transversely to the longitudinal direction of the core element to beyond this core element, 
- = prekrivanje ovog središnjeg elementa (1) trakom od fleksibilnog materijala koji se može impregnirati (2) i koji se nastavlja prema van poprijeko na uzdužni smjer središnjeg elementa (1) preko tog središnjeg elementa (1),
The coating material as recited in claim 1, wherein the polyol is selected from the group consisting of a polyacrylate-polyol, a polyester-polyol, a polyether-polyol, a polycarbonate-polyol, a polycaprolactone, and a polyurethane-polyol. 
Obložni materijal prema zahtjevu 1 ili 2, naznačen time, da su polioli odabrani iz skupine koju čine poliakrilat-polioli, poliester-polioli, polieter-polioli, polikarbonat-polioli, polikaprolaktoni i poliuretan-polioli.
R is C1-C4 linear alkyl or C3-C4 branched alkyl; or a pharmaceutically acceptable salt thereof 
R je C,-Ca nerazgranati alkil ili C3-Ca razgranati alkil; ili njegova farmaceutski prihvatljiva sol.
glycine (G) at amino acid position 95 using AHo numbering system (amino acid position 82b using Kabat numbering system); and 
X. - glicin (G) na poziciji 95 aminokiselina prema AHo sustavu numeriranja (pozicija 82b aminokiselina xi.
The pharmaceutical composition of claim 1 or 2 wherein the additional pH modifier is acetic acid. The pharmaceutical composition of any of claims 1 to 3 wherein the bulking agent consists of one or more bulking agents, and wherein said bulking agent is preferably mannitol, sucrose or a combination thereof. 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da se punilo za povećanje mase sastoji od jednog ili više sredstava za povećanje mase, te da je spomenuto punilo za povećanje mase poželjno manitol, saharoza ili njihova kombinacija.
As will be explained in the following, also a detaching action with regard to the mobile brewing head support 7 is mechanically and actively coupled to the main movement of the mobile brewing head support 7. 
Kao što će biti objašnjeno u sljedećem dijelu, također akcija odvajanja s obzirom na nosač pomične glave za pripremanje napitka 7 je mehanički i aktivno spojena na glavno kretanje nosača pomične glave za pripremanje napitka 7.
The composition according to claim 14, characterized in that further at least one hydrophobizing agent and/or at least one hydrophilizing agent, which may be the same as, or different from the agent used in the pre-treatment, is additionally added. 
Pripravak prema zahtjevu 14, naznačen time da se dodatno još dodaje barem jedno sredstvo za hidrofobiziranje i/ili barem jedno sredstvo za hidrofiliranje, koje može biti isto kao, ili se razlikuje od sredstva koje se koristi za prethodnu obradu.
the bus bar center conductor and the bus bar conductor are formed by any one of aluminum, copper, aluminum alloy, and copper alloy, and the bus bar insulator is formed by a mixture of organic and inorganic materials, or formed by an organic material. 
Sabirna tračnica (2) sukladno Zahtjevu 1, pri čemu: središnji vodič sabirne tračnice (21) i vodič sabirne tračnice (23, 25) su formirani od bilo kojeg od aluminija, bakra, legure aluminija, i legure bakra, i izolator sabirne tračnice (22, 24; 227) formiran je mješavinom organskih i anorganskih materijala, ili formiran pomoću organskog materijala.
The process according to claim 1, wherein the high density polyethylene post consumer resin is provided in flake form or in pellet form. 
Postupak prema bilo koejm zahtjevu pd 1 do 5 naznačeno time da neobrađeni bimodalni HDPE je snabdjeven u obliku praška ili peleta, poželjno u obliku praška.
The invention relates to a drink dispenser provided with a chamber with an opening for accommodating a container containing carbonated drink, which container is provided with an outlet closed by a shut-off valve and a tap head that during use is connected via a line to the outlet, which tap head has an operating member for opening and closing the line. 
HR P20070526 T3 OPIS IZUMA Izum se odnosi na djelitelj (raspršivač) pića opremljen komorom s otvorom u koji se smješta spremnik koji sadrži gazirano piće, čiji je spremnik opremljen izlaznim otvorom koji se zatvara ventilom i čija glava priključka ima aktivni element za otvaranje i zatvaranje dovoda.
A process according to [7], wherein the crystallization solvent is a mixed solvent of s-butyl alcohol and water (volume ratio=3.9:1-4.1:1). 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da je kristalizacijsko otapalo miješano otapalo s-butil alkohola i vode (omjer volumena = 3,9:1-4.1:1). .
In another aspect of the invention, the suitable solvent used in the crystallization step is selected from the group consisting of acetone, methanol, ethanol, propanol, water, ethyl acetate, i -propanol, butanol, i- butanol, s -butanol, t -butanol, hexane, toluene, t -butyl-methyl ether, trichloroethane and the like, and mixtures thereof. 
Prikladna otapala koja se koriste u kristalizacijskom koraku obdabiru se iz skupine koja se sastoji od acetona, metanola, etanola, propanola, vode, etilacetata, i-propanola, butanola, i-butanola, s-butanola, heksana, toluena, f-butil-metil etera i slično, i njihovih smjesa.
An immunogenic composition according to claim 1 in which said adjuvant further comprises any one or more of a sterol, a lipopolysaccharide and 1, 2-Dioleoyl-sn-Glycero-3-phosphocholine (DOPC). 
Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što navedeni adjuvans dodatno sadrži bilo koji od jednog ili više od sterola, lipopolisaharida i 1,2-dioleoil-sn-glicero-3-fosfokolina (DOPC).
A method for managing the automatic connection of a subscribed communication device to a network, the method comprising: 
Postupak za upravljanje automatskim osiguravanjem pretplatničke mrežne identifikacije sa centralnog mrežnog servera (108) pretplatničkom komunikacionom uređaju (10), pri čemu ovaj postupak obuhvaća:
A pharmaceutical composition comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, wherein the pharmaceutical composition is in a dosage form which provides a) a metered nominal dose of aclidinium equivalent to 400 micrograms plus/minus 10% aclidinium bromide, b) an emitted dose of aclidinium equivalent to 360 micrograms plus/minus 35% aclidinium bromide, or c) a fine particle dose of aclidinium equivalent to 120 micrograms plus/minus 35% aclidinium bromide, wherein the pharmaceutical composition is for inhalation. 
HR P20151214 T1 PATENTNI ZAHTJEVI Farmaceutski pripravak koji sadrži aklidinij u obliku suhog praha farmaceutski prihvatljive soli u smjesi s farmaceutski prihvatljivim nosačem suhog praha, pružajući odmjerenu nominalnu dozu aklidinija jednaku 400 ug (plus/minus 10 %) aklidinijevog bromida za primjenu inhalacijom u liječenju kronične opstruktivne plućne bolesti.
Use according to claim 1 wherein the compound of formula (I) is selected from the following compounds R1 R2 
Uporaba prema zahtjevu 1 naznačena time da spoj sa formulom (I) je odabran od slijedećih spojeva [image] [image] njihove farmaceutski prihvatljive kisele ili bazne adicijske soli ili njihovog N-oksida, te pri čemu:
Alzheimer's disease, Pick's disease, Progressive Supranuclear Palsy (PSP), frontotemporal dementia, parkinsonism linked to chromosome 17, disinhibition-dementiaparkinsonism-amyotrophy complex, pallido-ponto-nigral degeneration, Guam-ALS syndrome; pallido-nigro-luysian degeneration, cortico-basal degeneration, or 
Alzheimerova bolest, Pickova bolest, progresivna supranuklearna palsija (PSP), fronto-temporalna demencija, fronto-temporalna demencija s parkinsonizmom povezanim s kromosomom 17, mješavina disinhibicije, demencije, parkinsonizma i amiotrofije, palido-ponto-nigralna degeneracija, sindrom Guam-ALS, palido- nigro-luizijanska degeneracija, kortiko-bazalna degeneracija, ili
a polymeric material, wherein the polymeric material comprises polystyrene, polyvinyl chloride, polypropylene, polyethylene, polyamide, polycarbonate, or any combination thereof; or the sample: 
Postupak prema zahtjevu 5, naznačen time što supstrat sadrži polimerni materijal, pri čemu polimerni materijal sadrži polistiren, polivinil klorid, polipropilen, polietilen, poliamid, polikarbonat ili bilo koju njihovu kombinaciju.
Air is thus flowing into this space and it will be easier for the user to take out the capsule 1. 
Na taj način zrak protječe u taj prostor i biti će lakše za korisnika da izvadi čahuru 1.
The reaction was worked up by evaporating the reaction solution to approximately half its starting volume and diluting it in 300mL EtOAc and washing with water and dilute HCl solutions until the pH of the aqueous wash was approximately 7, then with brine. 
Reakcijska smjesa je bila dorađena uparavanjem reakcijske otopine do približno polovice njenog početnog volumena i njenim otapanjem u 300 mL EtOAc i ispiranjem s vodom i razrijeđenom otopinom HCI sve dok pH vode od ispiranja nije bio približno 7,1 tada sa slanom vodom.
The method of claim 1 wherein the slurry of bio-degradable components is subject to post-fermentation following separation of non-degradable solids. The Method of claim 1 wherein inoculation of the incoming MSW stream is provided by recycling wash waters or process solutions used to recover residual organic material from non-degradable solids. The method of claim 1 wherein inoculation of the incoming MSW stream is provided before or concurrently with the addition of enzymatic activities or with the addition of microorganisms that exhibit extra-cellular cellulase activity. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se mulj od biorazgradljivih komponenata podvrgava postfermentacijskoj obradi nakon odvajanje nerazgradljivih krutina. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što inokuliranje ulazne struje MSW se provodi recikliranjem voda od ispiranja ili procesnih otopina upotrijebljenih za prikupljanje preostalog organskog materijala iz nerazgradljivih krutina i/ili što se inokuliranje ulazne struje MSW provodi prije ili istodobno s dodavanjem enzimskih aktivnosti.
The compound of claim 1, wherein at least 50% of said compound is present in the form of its sodium salt compound. 
[image] pri čemu najmanje 50% od toga spoja je prisutno u obliku natrijeve soli od spoja prema zahtjevu 1, 2, 3, 4, 5, 6 ili 7.
The conjugate according to claim 3 wherein the chemical moiety that facilitates cellular uptake of the polypeptide or of the functionally equivalent variant thereof is a cell penetrating peptide and wherein said cell penetrating peptide and said polypeptide or the functionally equivalent variant thereof form a fusion protein. 
Polipeptid, ili njegova funkcionalno ekvivalentna varijanta, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što polipeptid, ili njegovu funkcionalno ekvivalentnu varijantu, treba primijeniti bez upotrebe vehikuluma za unos polipeptida u citoplazmu stanice.
arranging of washing and separating container (1) in such a way that the solid component is located next to the outlet (103); 
- < razmještanja spremnika (1) za ispiranje i odvajanje na takav način da je čvrsta komponenta pored odvoda -
The method according to claim 1, wherein the compound is coupled to a pharmaceutically acceptable carrier. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da je taj spoj povezan na farmaceutski prihvatljiv nosač, posebno na KLH (Keyhole Limpet Hemocyanin).
An LED module of claim 19, wherein said energy regulating circuit includes a microchip and a boosting circuit. 
LED modul iz patentnog zahtjeva 34, naznačen time, da navedeni sklop za regulaciju energije sadržava mikročip i kompenzacijski strujni krug.
The method of Claim 14, wherein said emuisifier is selected from the group consisting of a polysorbate, sucrose ester, stearoyl lactylate, mono/diglyceride, diacetyl tartaric ester of mono/di-glycerides, phospholipid, propylene glycol alginate, lipophilic modified starch, or mixture thereof. 
Postupak u skladu s patentnim zahtjevom 14, gdje navedeni emulgator se bira iz skupine koju čine polisorbat, saharozni ester, stearoil-laktilat, mono-/diglicerid, ester diacetilvinske kiseline s mono-/digliceridima, fosfolipid, propilen-glikol-alginat, lipofilno modificirani škrob, ili njihova smjesa.
a return line (112 ″) of the hot liquid fluid from the die to the second tank (111) through said three-way valve (EV 5). 
povratnu liniju (1127) tekućine za prethodno zagrijavanje iz kalupa u drugi spremnik (111) kroz trokraki ventil (EVS5).
Z is N or CR*, wherein R* is an optionally substituted alkyl, an optionally substituted acyl, an optionally substituted aryl or an optionally substituted heteroaryl; ring A is an optionally substituted aryl or an optionally substituted heteroaryl; ring B is an optionally substituted aryl or an optionally substituted heteroaryl; 
Zje N ili CR*, gdje R* je izborno supstituirani alkil, izborno supstituirani acil, izborno supstituirani aril ili izborno supstituirani heteroaril; prsten A je izborno supstituirani aril ili izborno supstituirani heteroaril; prsten B je izborno supstituirani aril ili izborno supstituirani heteroaril;
A compound of Formula (I), or a pharmaceutically acceptable salt, solvate or N- oxide thereof: wherein 
Spoj Formule (I), ili njegova farmaceutski prihvatljiva sol, solvat ili N-oksid:
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
A method of treating a condition selected from the group consisting of coronary obstructions, coronary artery disease (CAD), angina, heart attack, myocardial infarction, high blood pressure, ischemic cardiomyopathy and infarction, diastolic heart failure, pulmonary congestion, pulmonary edema, cardiac fibrosis, valvular heart disease, pericardial disease, circulatory congestive states, peripheral edema, ascites, Chagas' disease, ventricular hypertrophy, heart valve disease, heart failure, congestive heart failure, acute congestive heart failure, acute decompensated heart failure, pulmonary hypertension and cardiac hypertrophy, the method comprising administering to an individual in need thereof a therapeutically effective amount of a compound according to any one of claims 1, 9, 16 or 17 or a pharmaceutically acceptable salt thereof. 
10. Spoj bilo kojeg od patentnih zahtjeva od 1 do 7 ili njegova farmaceutski prihvatljiva sol za primjenu u liječenju stanja odabranih od kardiovaskularne bolesti ili srčane insuficijencije, koronarnih opstrukcija, koronarne arterijske bolesti (CAD), angine, srčanog napada, infarkta miokarda, visokog krvnog pritiska, ishemijske kardiomiopatije i infarkta, dijastolne srčane insuficijencije, plućne kongestije, edema pluća, srčane fibroze, bolesti srčanog zalistka, perikardijalne bolesti, cirkulatornih kongestivnih stanja, perifernog edema, ascitesa, Chagasove bolesti, ventrikularne hipertrofije, bolesti srčanog zalistka, srčane insuficijencije, kongestivne srčane insuficijencije, akutne kongestivne srčane insuficijencije, akutne dekompenzovane srčane insuficijencije, plućne hipertenzije i srčane hipertrofije, ishemije/reperfuzione povrede, i kancerogenih bolesti.
A dispenser according to claim 28 or 29, wherein the junction member (41) comprises one or more slots (450a, 450b), and the counter driver (206) comprises one or more protrusions (222a, 222b) for engaging with the junction member so as to couple the junction member and counter driver. 
Dispenzer u skladu sa patentnim zahtjevom 28 ili 29, gdje element (41) za povezivane sadrži jedan ili više proreza (4504, 450b), 1 pokretač (206) brojača sadrži jedno ili više ispupčenja (222a, 222b) za angažiranje sa elementom za povezivanje da bi se upario element za povezivanje sa pokretačem brojača.
adding to a thiolactone of the following formula VIII more than 1 equivalent of a Grignard reagent of the following formula IX to obtain a compound V; reducing the compound V; and if desired, deprotecting the resulting compound, in accordance with the following scheme: 
naznačen time da su Ar', Ar', A i R'-R'" kako je definirano u zahtjevu 1, te sadrži korake: dodavanja u tiolakton slijedeće formule VIII više od 1 ekvivalenta Grignardovog reagensa slijedeće formula IX da se dobije spoj V; redukciju spoja V; te ako se želi, deprotekcije dobivenog spoja, u skladu sa slijedećom shemom:
A process for the manufacture of a compound of the formula or acid addition salts thereof, the process comprising the steps of reacting a compound of the formula with ethyl chloroformate to obtain a compound of the formula which compound is further reacted with Et3SiH and trifluoro acetic acid followed by reaction with an acid to remove the N-piperidine protecting group and optionally to obtain a desired acid addition salt. 
HR P20120118 TI O BOR a taj spoj dalje reagira s EGSiH i trifluor octenom kiselinom, nakon čega slijedi reakcija s kiselinom da se ukloni N- piperidin zaštitna skupina i po izboru da se dobije željena kisela adicijska sol.